Results 181 to 190 of about 399,115 (333)
A CD169+ macrophage‐targeted immunomodulator (G‐LNP@S‐D) is developed to co‐deliver a SHP2 inhibitor and STING agonist, thereby restoring phagocytic function, enhancing antigen presentation by CD169+ macrophages, and promoting T cell priming to eradicate lymphatic metastasis.
Xiayun Chen +9 more
wiley +1 more source
Exploring Pembrolizumab-Induced IM3OS in a Patient With Bladder Cancer. [PDF]
Chan CC, Lee MJ, Su J, Su JJ.
europepmc +1 more source
Radiotherapy induces tumor cells to release microparticles (RT‐MPs) into the circulation. The mitochondrial DNA carried by these RT‐MPs activates the STING/NLRP3/GSDMD axis in splenic neutrophils, triggering IL‐1β secretion. This, in turn, enhances dendritic cell function and facilitates the formation of cytotoxic T lymphocytes, thereby promoting ...
Yan Hu +18 more
wiley +1 more source
Deciphering the Transcriptomic Signatures of Aging Across Organs in Mice. [PDF]
Morsy S +9 more
europepmc +1 more source
scPER presents an adversarial‐autoencoder framework that deconvolves bulk total RNA‐seq to quantify tumor‐microenvironment cell types and uncover phenotype‐linked subclusters. Across diverse benchmarks, scPER improves accuracy over existing tools.
Bingrui Li, Xiaobo Zhou, Raghu Kalluri
wiley +1 more source
Outcomes of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC: An International Multicentre Study. [PDF]
Kim JS +15 more
europepmc +1 more source

